Cell therapy for neurological disorders

被引:4
|
作者
Svendsen, Soshana P. [1 ]
Svendsen, Clive N. [1 ]
机构
[1] Cedars Sinai Board Governors Regenerat Med Inst, Los Angeles, CA 90048 USA
关键词
NEURAL STEM-CELLS; AMYOTROPHIC-LATERAL-SCLEROSIS; FETAL NIGRAL TRANSPLANTATION; SPINAL-CORD-INJURY; PARKINSONS-DISEASE; DOPAMINE NEURONS; HUNTINGTONS-DISEASE; PROGENITOR CELLS; PRECLINICAL EFFICACY; PRECURSOR CELLS;
D O I
10.1038/s41591-024-03281-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cell therapies for neurological disorders are entering the clinic and present unique challenges and opportunities compared with conventional medicines. They have the potential to replace damaged nervous tissue and integrate into the brain or spinal cord to produce functional effects for the lifetime of the patient, which could revolutionize the way clinicians treat debilitating neurological disorders. The major challenge has been cell sourcing, which historically relied mainly on fetal brain tissue. This has largely been overcome with the advent of pluripotent stem cell technology and the ability to make almost any cell of the nervous system at scale. Furthermore, advances in gene editing now allow the generation of genetically modified cells that could perform better and evade the immune system. With all the remarkable new approaches to treat neurological disorders, we take a critical look at the state of current clinical trials and how challenges may be overcome with the evolving technology and innovation occurring in the stem cell field. This Review summarizes the state of clinical research on cell replacement therapy for neurological conditions, and discusses the challenges facing the field, from immunosuppression and therapeutic delivery to cost issues.
引用
收藏
页码:2756 / 2770
页数:15
相关论文
共 50 条
  • [41] The biological clock: future of neurological disorders therapy
    Gaikwad, Sagar
    NEURAL REGENERATION RESEARCH, 2018, 13 (03) : 567 - 568
  • [42] Targeting cellular energy production in neurological disorders
    Baker, SK
    Tarnopolsky, MA
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (10) : 1655 - 1679
  • [43] Mitophagy in neurological disorders
    Zhang, Lijun
    Dai, Lei
    Li, Deyuan
    JOURNAL OF NEUROINFLAMMATION, 2021, 18 (01)
  • [44] Telomeres in neurological disorders
    Anitha, Ayyappan
    Thanseem, Ismail
    Vasu, Mahesh Mundalil
    Viswambharan, Vijitha
    Poovathinal, Suresh A.
    ADVANCES IN CLINICAL CHEMISTRY, VOL 90, 2019, 90 : 81 - 132
  • [45] Genetics of neurological disorders
    Faghihi, MA
    Mottagui-Tobor, S
    Wahlestedt, C
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2004, 4 (03) : 317 - 332
  • [46] Neurological disorders and mitochondria
    Cabral-Costa, J. V.
    Kowaltowski, A. J.
    MOLECULAR ASPECTS OF MEDICINE, 2020, 71
  • [47] Circulating Metabolites as Potential Biomarkers for Neurological Disorders-Metabolites in Neurological Disorders
    Donatti, Amanda
    Canto, Amanda M.
    Godoi, Alexandre B.
    Rosa, Douglas C.
    Lopes-Cendes, Iscia
    METABOLITES, 2020, 10 (10) : 1 - 32
  • [48] Promises and limitations of immune cell-based therapies in neurological disorders
    Hu, Xiaoming
    Leak, Rehana K.
    Thomson, Angus W.
    Yu, Fang
    Xia, Yuguo
    Wechsler, Lawrence R.
    Chen, Jun
    NATURE REVIEWS NEUROLOGY, 2018, 14 (09) : 559 - 568
  • [49] Ferroptosis, a Recent Defined Form of Critical Cell Death in Neurological Disorders
    Wu, Jia-rui
    Tuo, Qing-zhang
    Lei, Peng
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2018, 66 (02) : 197 - 206
  • [50] Human embryonic stem cells. Perspectives for the study and therapy of neurological disorders
    Nolden, L.
    Bruestle, O.
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2008, 51 (09) : 1026 - 1032